Skip to main content

Advertisement

Open Peer Review Reports for: Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
21 Jun 2011 Submitted Original manuscript
1 Aug 2011 Reviewed Reviewer Report - shubhada chiplunkar
2 Aug 2011 Reviewed Reviewer Report - Claudia Palena
17 Aug 2011 Reviewed Reviewer Report - Tyler Curiel
23 Sep 2011 Author responded Author comments - jason chesney
Resubmission - Version 2
23 Sep 2011 Submitted Manuscript version 2
23 Sep 2011 Author responded Author comments - jason chesney
Resubmission - Version 3
23 Sep 2011 Submitted Manuscript version 3
Resubmission - Version 4
Submitted Manuscript version 4
Resubmission - Version 5
Submitted Manuscript version 5
7 Oct 2011 Reviewed Reviewer Report - Claudia Palena
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
13 Dec 2011 Editorially accepted
13 Dec 2011 Article published 10.1186/1471-2407-11-515

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement